<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/121517</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Systems Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glycosylation flux analysis reveals dynamic changes of intracellular glycosylation flux distribution in Chinese hamster ovary fed-batch cultures</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hutter</surname>
<given-names>Sandro</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a2">b</xref>
<xref ref-type="author-notes" rid="n1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Villiger</surname>
<given-names>Thomas K.</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="author-notes" rid="n1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Br&#x00FC;hlmann</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="a3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stettler</surname>
<given-names>Matthieu</given-names>
</name>
<xref ref-type="aff" rid="a3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broly</surname>
<given-names>Herv&#x00E9;</given-names>
</name>
<xref ref-type="aff" rid="a3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soos</surname>
<given-names>Miroslav</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a4">d</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gunawan</surname>
<given-names>Rudiyanto</given-names>
</name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a2">b</xref>
<xref ref-type="corresp" rid="cor1">2</xref>
</contrib>
<aff id="a1"><label>a</label><institution>Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences</institution>, ETH Zurich, 8093 Zurich, <country>Switzerland</country></aff>
<aff id="a2"><label>b</label><institution>Swiss Institute of Bioinformatics</institution>, 1015 Lausanne, <country>Switzerland</country></aff>
<aff id="a3"><label>c</label><institution>Biotech Process Sciences, Merck Biopharma</institution>, 1804 Corsier-sur-Vevey, <country>Switzerland</country></aff>
<aff id="a4"><label>d</label><institution>Department of Chemical Engineering, University of Chemistry and Technology</institution>, 166 28 Prague, Czech Republic</aff></contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>1</label><p>Contributed equally</p></fn>
<corresp id="cor1"><label>2</label>Corresponding author: <email>rudi.gunawan@chem.ethz.ch</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2017</year>
</pub-date>
<elocation-id>121517</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2017, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="121517.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>N-linked glycosylation of proteins has both functional and structural significance. Importantly, the glycan structure of a therapeutic protein influences its efficacy, pharmacokinetics, pharmacodynamics and immunogenicity. In this work, we developed glycosylation flux analysis (GFA) for predicting intracellular production and consumption rates (fluxes) of glycoforms, and applied this method to CHO fed-batch monoclonal antibody (mAb) production using two different media compositions, with and without additional manganese feeding. The GFA is based on a constraint-based modelling of the glycosylation network, employing a pseudo steady state assumption. While the glycosylation fluxes in the network are balanced at each time point, the GFA allows the fluxes to vary with time by way of two scaling factors: (1) an enzyme-specific factor that captures the temporal changes among glycosylation reactions catalyzed by the same enzyme, and (2) the cell specific productivity factor that accounts for the dynamic changes in the mAb production rate. The GFA of the CHO fed-batch cultivations showed that regardless of the media composition, the fluxes of galactosylation decreased with the cultivation time in comparison to the other glycosylation reactions. Furthermore, the GFA showed that the addition of Mn, a cofactor of galactosyltransferase, has the effect of increasing the galactosylation fluxes but only during the beginning of the cultivation period. The results thus demonstrated the power of the GFA in delineating the dynamic alterations of the glycosylation fluxes by local (enzyme-specific) and global (cell specific productivity) factors.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>N-linked glycosylation</kwd>
<kwd>flux analysis</kwd>
<kwd>CHO cells</kwd>
<kwd>constraint-based modeling</kwd>
<kwd>monoclonal antibody</kwd>
</kwd-group>
<counts>
<page-count count="38"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Introduction</title>
<p>The introduction of Quality by Design (QbD) and Process Analytical Technology (PAT) initiatives by the US Food and Drug Administration has driven a resurgence in research efforts and innovation in biopharmaceutical process development and manufacturing (<xref ref-type="bibr" rid="c8">FDA, 2004</xref>; <xref ref-type="bibr" rid="c27">Rathore, 2009</xref>). QbD and PAT prescribe continuous process improvements through well-defined process objectives, science-based product and process understanding, timely (online) process measurements, and process system design, analysis and control. In the current competitive and burgeoning market for therapeutic proteins and biosimilars, the biopharmaceutical industry faces numerous challenges in ensuring product quality, shortening time to market, improving cost effectiveness and creating manufacturing flexibility (<xref ref-type="bibr" rid="c21">Li et al., 2010</xref>). One of the most important quality attributes of recombinant therapeutic proteins is the structure of the asparagine-linked oligosaccharide sugar or N-linked glycan attached to the proteins. This glycan structure can influence protein folding (<xref ref-type="bibr" rid="c1">Aebi, 2013</xref>), secretion (<xref ref-type="bibr" rid="c37">Zhang and Kaufman, 2006</xref>) and stability (<xref ref-type="bibr" rid="c4">Arosio et al., 2013</xref>), and has an impact on bio-activity (<xref ref-type="bibr" rid="c35">Uma&#x00F1;a et al., 1999</xref>), efficacy (<xref ref-type="bibr" rid="c10">Goh et al., 2014</xref>) and immunogenicity (<xref ref-type="bibr" rid="c13">Harding et al., 2010</xref>). Consequently, the regulation and control of N-linked glycosylation has received much attention from the biopharmaceutical industry.</p>
<p>The N-linked glycan of a protein is processed post-translationally in the rough endoplasmic reticulum (ER) and Golgi cisternae. There exists a natural heterogeneity in the outcome of the glycosylation process. The biosynthetic pathways of N-linked glycosylation processing in the Golgi involve a relatively small number of enzymes, and therefore, minor alterations in the activities of these enzymes can cause significant changes in the resulting glycan profile (i.e. the distribution of the glycan structures) of a protein, sometimes with detrimental consequences (<xref ref-type="bibr" rid="c2">Aebi and Hennet, 2001</xref>). The glycan profile has been shown to depend on, among other things, cell culture parameters (e.g., dissolved oxygen, pH, temperature, osmolality), culture media composition, and expression hosts (<xref ref-type="bibr" rid="c16">Hossler et al., 2009</xref>; <xref ref-type="bibr" rid="c17">Ivarsson et al., 2014</xref>). Yet, the mechanisms of these dependencies still remain unclear. Transcriptomics, proteomics and metabolomics analysis have been used to get a better picture of the intracellular changes in protein glycosylation, caused by modifications in the cell culture conditions (<xref ref-type="bibr" rid="c28">Sha et al., 2016</xref>). Furthermore, mathematical models of the glycosylation network have been created to explain the observed glycoform profiles and to predict the glycosylation outcome (<xref ref-type="bibr" rid="c19">Jimenez del Val et al., 2011</xref>; <xref ref-type="bibr" rid="c22">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="c32">St Amand et al., 2014</xref>; <xref ref-type="bibr" rid="c34">Uma&#x00F1;a and Bailey, 1997</xref>) Recent modelling efforts have focused on linking extracellular metabolite measurements to the protein glycosylation process by coupling the dynamic model of the bioreactor with the intracellular model of glycan metabolism and glycosylation network (<xref ref-type="bibr" rid="c18">Jedrzejewski et al., 2014</xref>). However, these detailed models comprised partial differential equations and possessed a large number of unknown kinetic parameters, posing a challenge in model simulations and parameter estimation.</p>
<p>On the opposite spectrum of modelling framework, the constraint-based modelling (CBM) uses a simple and parameter-free approach, requiring only the stoichiometry of the reactions to make predictions on the reaction fluxes. The most successful application of CBM has been in the modelling and analysis of intracellular metabolism. By assuming that the metabolic reaction network operates under steady state, the metabolic fluxes can be estimated from the measurements of extracellular metabolites using metabolic flux analysis (MFA) (when the estimation problem is over-determined) (<xref ref-type="bibr" rid="c11">Goudar et al., 2007</xref>) or using flux balance analysis (FBA) (when the estimation problem is under-determined) (<xref ref-type="bibr" rid="c24">Orth et al., 2010</xref>). In the FBA, one makes a further assumption that the cell organizes its metabolic flux distribution to optimize a particular objective (e.g. biomass production). While MFA and FBA have been routinely used to analyze metabolic network models, they are not yet commonly used to study protein glycosylation. A recent constraint-based modelling of protein glycosylation adopted a probabilistic approach using the Markov chain theory to explore feasible fluxes that could explain the observed glycan distribution, thereby avoiding the need to assign a cellular objective as in the FBA (<xref ref-type="bibr" rid="c30">Spahn et al., 2015</xref>). The method was developed specifically for predicting the protein glycosylation outcome from enzyme knock-out(s), and has been extended to glycoengineering by strain optimization (<xref ref-type="bibr" rid="c31">Spahn et al., 2017</xref>). While these works demonstrated the promise of CBM for glycoengineering application, the strategy was not designed for predicting the (dynamical) changes in the regulation of glycosylation fluxes due to alterations in the cell culture conditions and parameters (e.g., media compositions, pH, etc.).</p>
<p>In this work, we present a novel constraint-based modelling approach for analyzing protein glycosylation fluxes. The method, called Glycosylation Flux Analysis (GFA), generates predictions for the (intracellular) glycosylation reaction fluxes from the secretion rates of glycoforms. The GFA is based on the premise that the temporal variations in the intracellular glycosylation fluxes are the results of time-varying changes in the enzyme-specific factors (such as gene expression, enzyme activity and nucleotide sugar availability) and in the cell metabolism (especially the specific productivity). Finally, we applied the GFA to elucidate the dynamical changes of immunoglobulin G (IgG) glycosylation in fed-batch CHO cell cultures using two different media compositions (without and with manganese feed).</p>
</sec>
<sec id="s2">
<label>2.</label>
<title>Materials and Methods</title>
<sec id="s2a">
<label>2.1</label>
<title>Cell culture conditions</title>
<p>CHO-S cells producing an IgG monoclonal antibody were cultivated in a 3 L bench scale bioreactor system (Sartorius Stedim, Germany). The resulting antibody bore two N-linked glycosylation sites at the Fc region. Cells were first expanded in shake bottles and the cell seeding density was set to 0.3&#x00D7;10<sup>6</sup> cells/mL. A temperature shift from 36.5 &#x00B0;C to 33.0 &#x00B0;C and a pH shift from 7.1 to 6.9 were conducted on the fifth culture day. CO2 was used to control the pH and the dissolved oxygen set point was fixed to 50 &#x0025; air saturation. Feeds were added on day 3, 5, 7 and 10 and consisted of a proprietary concentrated main feed with over 30 components, a highly alkaline amino acid solution and a glucose solution of 400 g/L. The main feed in the first experiment (process A) represented a control experiment, whereas the main feed in the second experiment (process B) had a different amino acid composition with manganese chloride addition. The final concentration of MnCl in process B was set to 2.4 &#x03BC;mol per liter culture volume.</p>
</sec>
<sec id="s2b">
<label>2.2</label>
<title>Analytical methods for cell cultures and product quality analysis</title>
<p>Cell counts and cell viability were measured with a Vi-Cell analyzer (Bechman Coulter, Brea, CA), and metabolites were quantified with a Nova CRT (Nova Biomedical, Waltham, MA). A NOVA BioProfile pHOx analyzer (Nova Biomedical, Waltham, MA) was used to determine pH, pO2 and pCO2. The antibody concentration was determined on a Biacore C instrument (GE Healthcare, Waukesha, WI). Protein glycosylation of Phytips eluates (Phytips<sup>&#x00AE;</sup>, PhyNexus, San Jose, CA, USA) was analyzed by Ultra Performance Liquid Chromatography (UPLC)-2-amino-benzamide labelling technique. A 100 mm HILIC column was supplied by Waters Corporation, Milford, MA, USA. Samples at working day 3, 4, 5 and 6 were concentrated prior to analysis using 5 kDa MWCO vivaspins (Sartorius Stedim, Germany).</p>
</sec>
<sec id="s2c">
<label>2.3</label>
<title>Data Pre-processing</title>
<p>The glycosylation flux analysis uses the secretion fluxes (rates) of protein glycoforms as inputs to make predictions on the intracellular glycosylation fluxes. For this purpose, the cell culture data of viable cell density (<italic>X<sub>v</sub></italic>(<italic>t</italic>) [10<sup>6</sup> cells/mL]), mAb concentration (<italic>T</italic>(<italic>t</italic>) [g/L]) and glycan fractions (<italic>f<sub>i</sub></italic>(<italic>t</italic>) [&#x0025;]) were pre-processed to produce the required secretion fluxes. First, the concentration of each glycoform was computed from the temporal data of mAb titer and the fraction of the glycoforms as follows:
<disp-formula id="eqn1"><alternatives><graphic xlink:href="121517_eqn1.gif"/></alternatives></disp-formula> where <italic>c<sub>E,i</sub></italic>(<italic>t</italic><sub><italic>k</italic></sub>) denotes the extracellular concentration of the <italic>i</italic>-th glycoform at the <italic>k</italic>-th time point (<italic>k</italic> &#x003D; 1, 2, &#x2026;,<italic>K</italic>) and <italic>MW<sub>i</sub></italic> denotes the molecular weight of the <italic>i</italic>-th glycoform. Since the contribution of glycans to the molecular weight of the protein was insignificant, the protein&#x2019;s molecular weight was used for the calculations above (MW IgG &#x003D; 150 kDa). The glycoform concentrations were smoothened using a sigmoidal Hill-type function:
<disp-formula id="eqn2"><alternatives><graphic xlink:href="121517_eqn2.gif"/></alternatives></disp-formula> where the parameters <italic>a, b, d</italic> and <italic>n</italic> were determined by minimizing the sum of squares of the difference between the smoothing function and the concentration data. Finally, the time slopes of the glycoform concentration <italic>dc<sub>E,i</sub></italic>(<italic>t</italic>)/<italic>dt</italic> were evaluated using the first-order derivative of the aforementioned smoothing function.</p>
<p>Meanwhile, the viable cell density data were smoothened using a logistic function, given by: (<xref ref-type="bibr" rid="c12">Goudar et al., 2005</xref>):
<disp-formula id="eqn3"><alternatives><graphic xlink:href="121517_eqn3.gif"/></alternatives></disp-formula> where the parameters <italic>A, B, C</italic> and <italic>D</italic> were obtained by minimizing the sum of squares of the difference between the logistic function above and <italic>X<sub>v</sub></italic> data. Given <italic>dc<sub>E,i</sub></italic>(<italic>t</italic>)<italic>/dt</italic> and <italic>X<sub>v</sub></italic>(<italic>t</italic>) from the above data smoothening steps, the secretion fluxes of each glycoform <italic>v<sub>E,i</sub></italic>(<italic>t</italic>) were computed according to:
<disp-formula id="eqn4"><alternatives><graphic xlink:href="121517_eqn4.gif"/></alternatives></disp-formula></p>
<p>Note that in the above derivations, we assumed a constant volume of the cell culture. For the fed-batch experiments that we considered, such an assumption was reasonable since the cell culture volume varied only slightly with time (see SI Figure 1). When the volume of the cell culture varies strongly with time, the secretion flux calculation should take into account the volumetric changes, as follow:
<disp-formula id="eqn5"><alternatives><graphic xlink:href="121517_eqn5.gif"/></alternatives></disp-formula> where <italic>V</italic>(<italic>t</italic>) is the cell culture volume at time <italic>t</italic>.</p>
</sec>
<sec id="s2d">
<label>2.4</label>
<title>Glycosylation Flux Analysis</title>
<p>The glycosylation flux analysis (GFA) gives predictions for the intracellular fluxes of the glycosylation network (see <xref ref-type="fig" rid="fig1">Figure 1</xref>) under a pseudo steady state assumption based on a constraint-based modelling approach, as follow:
<disp-formula id="eqn6"><alternatives><graphic xlink:href="121517_eqn6.gif"/></alternatives></disp-formula> where <italic>c</italic><sub><italic>I,i</italic></sub> denotes the (internal) concentration of the <italic>i</italic>-th glycoform, <italic>v</italic><sub><italic>I,j</italic></sub> denotes the (internal) flux of the <italic>j</italic>-th glycosylation reaction, <italic>v<sub>E,i</sub></italic> denotes the (external) secretion flux of the <italic>i</italic>-th glycoform, and <italic>S</italic>(<italic>i</italic>,<italic>j</italic>) is the number of molecules of the i-th glycoform that is consumed (when <italic>S</italic>(<italic>i,j</italic>) &#x003C; 0) or produced (when <italic>S</italic>(<italic>i,j</italic>) &#x003E; 0) by the <italic>j</italic>-th reaction. The pseudo steady state assumption is reasonable as the residence time of Golgi apparatuses between 20-40 minutes (<xref ref-type="bibr" rid="c5">Bibila and Flickinger, 1991</xref>; <xref ref-type="bibr" rid="c15">Hirschberg and Lippincott-Schwartz, 1999</xref>), is much shorter than the time scale of the cell culture dynamics (on the order of days). The relationship above can be written in a matrix-vector format as follows:
<disp-formula id="eqn7"><alternatives><graphic xlink:href="121517_eqn7.gif"/></alternatives></disp-formula> where <bold>S</bold> denotes the stoichiometric matrix of the network, and <bold>v</bold><sub><italic>I</italic></sub>(<italic>t</italic>) and <bold>v</bold><sub><italic>E</italic></sub>(<italic>t</italic>) denote the vectors of glycosylation and secretion fluxes of the protein glycoforms, respectively. The stoichiometric matrix is an <italic>m</italic> by <italic>n</italic> matrix where <italic>m</italic> is the number of protein glycoforms and <italic>n</italic> is the number of reactions in the network. Based on <xref ref-type="disp-formula" rid="eqn7">Eq. (7)</xref>, the values of the glycosylation fluxes at each time point <italic>t<sub>k</sub></italic> can be computed directly from the secretion fluxes of the glycoforms <bold>v</bold><sub><italic>E</italic></sub>(<italic>t</italic><sub><italic>k</italic></sub>) when the stoichiometric matrix <bold>S</bold> is invertible or has a full column rank. Given that the glycosylation enzymes can act on multiple substrates, the number of reaction exceeds the number of structures in the glycosylation network (i.e. <italic>m</italic> is smaller than <italic>n</italic>). In other words, the stoichiometric matrix is not invertible and the calculation of the internal glycosylation fluxes is an underdetermined problem.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1</label>
<caption>
<p>N-linked glycosylation network for immunoglobulin G in CHO-S. The glycosylation network model consists of 19 measured glycoforms (excluding M9) with 25 glycosylation reactions and represents the smallest network that includes all measured and intermediate glycoforms. The glycoform M9 is not required for the determination of intracellular glycosylation fluxes. The color of the arrows refers to the glycosylation enzymes which catalyze the corresponding flux.</p>
</caption>
<graphic xlink:href="121517_fig1.tif"/>
</fig>
<p>In order to resolve the underdetermined problem above, we assume that the temporal changes in the glycosylation fluxes <bold><italic>V</italic></bold><sub><italic>I</italic></sub> are the result of (i) local enzyme-specific alterations and (ii) global dynamical changes in the cell metabolism. Based on this assumption, we write the time evolution of internal glycosylation fluxes as follow:
<disp-formula id="eqn8"><alternatives><graphic xlink:href="121517_eqn8.gif"/></alternatives></disp-formula> where <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) denotes the enzyme-specific (local) factor, <italic>&#x03B2;</italic>(<italic>t</italic>) denotes the cell specific (global) factor, and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline1.gif"/></alternatives></inline-formula> denotes the reference flux value for the <italic>j</italic>-th internal flux <italic>v</italic><sub><italic>I,j</italic></sub>. The enzyme-specific factor <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) is shared among all reactions catalysed by the same enzyme <italic>J</italic>, while the cell factor <italic>&#x03B2;</italic>(<italic>t</italic>) applies to all reactions in the glycosylation network. The factors <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) and <italic>&#x03B2;</italic>(<italic>t</italic>) represent the time-dependent fold-amplification or -attenuation of the glycosylation fluxes, and hence their values can be normalized with respect to those at an arbitrary reference time point <italic>t<sub>ref</sub></italic>. Without loss of generality, in this work we used the first measurement time point as the reference time, and thus assigned all <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic><sub>1</sub>) and <italic>&#x03B2;</italic>(<italic>t</italic><sub>1</sub>) to 1.</p>
<p>The factors <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) capture the dynamical alterations of glycosylation fluxes through local (enzyme-specific) factors such as enzyme expression, activity, inhibition, and nucleotide sugar availability. On the other hand, the variable <italic>&#x03B2;</italic>(<italic>t</italic>) describes the influence of the global cell metabolism on the glycosylation network, in particular the dynamical changes in the specific productivity of the cells. Therefore, we computed <italic>&#x03B2;</italic>(<italic>t</italic>) as the ratio between the specific productivity (<italic>q<sub>mAb</sub></italic>) at time <italic>t</italic> and that at time <italic>t<sub>ref</sub></italic>, as follows:
<disp-formula id="eqn9"><alternatives><graphic xlink:href="121517_eqn9.gif"/></alternatives></disp-formula></p>
<p>Given the relationships in <xref ref-type="disp-formula" rid="eqn8">Eqs. (8)</xref> and <xref ref-type="disp-formula" rid="eqn9">(9)</xref>, the calculation of the internal glycosylation fluxes reduces to fitting <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline2.gif"/></alternatives></inline-formula> to the secretion flux values, according to:
<disp-formula id="eqn10"><alternatives><graphic xlink:href="121517_eqn10.gif"/></alternatives></disp-formula></p>
<p>The schematic of the GFA workflow is depicted in <xref ref-type="fig" rid="fig2">Figure 2</xref>. The number of optimization variables above is <italic>n</italic><sub><italic>J</italic></sub>(<italic>K</italic> &#x2212; 1) &#x002B; <italic>n</italic>, where <italic>n</italic><sub><italic>J</italic></sub> is the number of enzymes in the glycosylation network. As long as the total number of secretion flux values is larger than or equal to the number of unknowns above (i.e., <italic>mK</italic> &#x2265; <italic>n</italic><sub><italic>J</italic></sub>(<italic>K</italic> &#x2212; 1) &#x002B; <italic>n</italic>), the GFA problem is over- or fully-determined, respectively. In this work, the optimization in the GFA was solved in MATLAB by using a global optimization method called the enhanced scatter search method from the MEIGO toolbox (<xref ref-type="bibr" rid="c7">Egea et al., 2014</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2</label>
<caption>
<p>The GFA workflow. In the data pre-processing step, measurements of viable cell density (<italic>X</italic><sub><italic>v</italic></sub>(<italic>t</italic>)), titer (<italic>T</italic>(<italic>t</italic>)) and the glycan fractions (<italic>f</italic><sub><italic>i</italic></sub>(<italic>t</italic>)) are smoothened for the computation of the secretion fluxes of the glycoforms and the specific productivity of the cells <italic>&#x03B2;</italic>(<italic>t</italic>). The GFA predicts the intracellular fluxes by optimizing over the values of the enzyme specific factors <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t<sub>k</sub></italic>) and the reference flux values <inline-formula><alternatives><inline-graphic xlink:href="121517_inline3.gif"/></alternatives></inline-formula>.</p>
</caption>
<graphic xlink:href="121517_fig2.tif"/>
</fig>
<p>For quantifying the uncertainty in the estimated <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t<sub>k</sub></italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline4.gif"/></alternatives></inline-formula>, we generated 10 synthetic datasets for each process, consisting of glycoform concentrations and <italic>X<sub>v</sub></italic> values at the same measurement time points, by contaminating the actual data with independent and identically distributed noise from a Gaussian distribution. We used the residuals from the data smoothening step to compute the variance of the noise for each variable. Finally, for each synthetic dataset, we carried out the GFA in the same manner as described above. In the application of the GFA to CHO fed-batch cultivation below, we reported the optimized <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t<sub>k</sub></italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline5.gif"/></alternatives></inline-formula> along with the standard deviation evaluated using the GFA results of the synthetic datasets.</p>
</sec>
</sec>
<sec id="s3">
<label>3.</label>
<title>Results</title>
<sec id="s3a">
<label>3.1</label>
<title>Cell culture data</title>
<p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows the cell culture measurements of the viable cell density, IgG concentration and glycoform distribution (fractions) from process A and B. The logistic function smoothing for <italic>X</italic><sub><italic>v</italic></sub>(<italic>t</italic>) appears as solid lines in the figure above. The cell density in process A reached a peak of &#x223C;20&#x00D7;10<sup>6</sup> cells/mL on day 7, while the peak cell density of process B was higher at &#x223C;25&#x00D7;10<sup>6</sup> cells/mL and occurred on day 8. While the viable cell density in process A was lower than that in process B, both processes had a similar final IgG concentration of &#x223C;3 g/L. The logistic function could describe the overall temporal variation in the viable cell density data reasonably well (SI Table 1). A more detailed comparison between the two process datasets is provided in SI <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3</label>
<caption>
<p>Cell culture measurements of the viable cell density (filled symbols), IgG titer (empty symbols) and glycoform distribution using (A, red) the standard culture media and (B, blue) the alternative media with Mn addition. The solid lines show the logistic function curve fitting for the viable cell density (see Methods).</p>
</caption>
<graphic xlink:href="121517_fig3.tif"/>
</fig>
<p>The time evolution of the IgG glycan distribution in both processes showed an increase of less processed glycan fractions toward the end of the cell culture duration, in agreement with previous studies using the same cell line (<xref ref-type="bibr" rid="c3">Aghamohseni et al., 2014</xref>; <xref ref-type="bibr" rid="c25">Pacis et al., 2011</xref>). While such a trend was observed for the entire cell culture duration in process A, this trend was reversed in the first half of process B. More precisely, between day 3 and 6, we observed an increase in the fraction of galactosylated glycan structures. This observation agreed with a previous study investigating the effect of manganese addition using real-time glycosylation monitoring (<xref ref-type="bibr" rid="c33">Tharmalingam et al., 2015</xref>). Manganese is a cofactor of many Golgi resident enzymes, including N-acetylglucosaminyltransferases I/II and galactosyltransferases (<xref ref-type="bibr" rid="c14">Hendrickson and Imperiali, 1995</xref>).</p>
</sec>
<sec id="s3b">
<label>3.2</label>
<title>GFA of CHO Fed-batch Cultivation</title>
<p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows the glycosylation network used in the GFA of CHO-S cell culture. The network was derived from a previous publication (<xref ref-type="bibr" rid="c36">Villiger et al., 2016</xref>), in which undetectable and non-intermediate glycoforms were removed (<xref ref-type="bibr" rid="c29">Shah et al., 2008</xref>). In the GFA, we considered the glycosylation flux balances around all protein glycoforms downstream of M8 (including M8), which corresponded to <italic>m</italic> = 19 glycoforms and <italic>n</italic> = 25 reactions (see SI Text A for the glycosylation network model). For <italic>K</italic> = 11 time points, the number of secretion flux values (209) was larger than the number of unknowns (95), and hence the GFA was over-determined. A few of the glycoforms in the network (M8, AM5, FAM5, FA2G1-1S1, FA2G1-2S1, FA2G2S1-2) were undetected, and thus we set the corresponding secretion rates to 0. <xref ref-type="fig" rid="fig4">Figure 4</xref> shows the concentration time profiles of the glycoforms and the corresponding Hill-type smoothing curves for the two process conditions.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4</label>
<caption>
<p>Calculated glycoform concentrations in process A (red, solid symbols) and process B (blue, empty symbols). The lines show the Hill-type smoothing function.</p>
</caption>
<graphic xlink:href="121517_fig4.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig5">Figure 5</xref> depicts the secretion fluxes of the glycoforms (in solid lines) after the data pre-processing. The secretion fluxes from the GFA are also drawn on the same figure, showing a good agreement with the smoothened flux values. As expected from the least square optimization in <xref ref-type="disp-formula" rid="eqn10">Eq. (10)</xref>, the secretion fluxes of the main glycoforms with larger magnitudes, particularly FA2, were better reproduced by the GFA than others. While one could use a weighted least square optimization to obtain a better agreement with secretion fluxes of lower magnitudes, such a strategy would come at the cost of worse agreement for the fluxes producing the dominant glycan structures (results not shown).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5</label>
<caption>
<p>Fitting of glycoform secretion fluxes in GFA. The GFA gives accurate predictions of the secretory fluxes of glycoforms in process A (red, solid symbols) and process B (blue, empty symbols). The lines show the smoothened secretion fluxes in process A (red line) and process B (blue line).</p>
</caption>
<graphic xlink:href="121517_fig5.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig6">Figure 6</xref> describes the time profiles of the enzyme-specific factors <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), the cell specific productivity <italic>&#x03B2;</italic>(<italic>t</italic>), and the reference fluxes <inline-formula><alternatives><inline-graphic xlink:href="121517_inline6.gif"/></alternatives></inline-formula> for process A and B. The cell specific productivity in the two processes generally increased with the cultivation time, with process A having a slightly higher fold-increase. The GFA predicted the enzyme-specific factor of galactosyltransferase GalT to decrease during much of the fed-batch cultivation period in both processes. The enzyme-specific factors of the other enzymes (ManI/II, GnTI/II, FucT) remained at an approximately constant level. A decrease in GalT activity is a frequently observed phenomena in industrial fed-batch processes of CHO-S culture (<xref ref-type="bibr" rid="c9">Gawlitzek et al., 2000</xref>), because of the adverse environmental conditions to which the cells are exposed (e.g., by-products, nutrient limitation and overfeeding, osmotic stress). As shown previously, the activity of GalT (and SiaT) for the cell line under investigation is much more sensitive to extracellular environment compared to ManI/II, GnTI/II and FucT (<xref ref-type="bibr" rid="c36">Villiger et al., 2016</xref>). In this regard, the accumulation of ammonia during the course of the cell culture (see SI <xref ref-type="fig" rid="fig2">Figure 2</xref>) could cause a pH increase in the Golgi, leading to a decrease in the GalT activity. The GFA of process A showed a slight increase in <italic>&#x03B1;</italic><sub><italic>GalT</italic></sub>(<italic>t</italic>) between day 3 and 6, but such an increase was not statistically significant (H0: <italic>&#x03B1;</italic><sub><italic>GalT</italic></sub>(<italic>t</italic>) &#x003D; 1 has a <italic>p</italic> value larger than 0.05). Also, the drop in the GalT-specific factor explained the increase of FA2 and the decrease of galactosylated glycan structures towards the end of the two fed-batch cultivations. The flux values of reactions catalyzed by SiaT were not shown since these fluxes were predicted to be near zero (see SI Figure 3).</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6</label>
<caption>
<p>The GFA of process A and B: <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), <italic>&#x03B2;</italic>(<italic>t</italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline7.gif"/></alternatives></inline-formula>. The error bars correspond to the standard deviation in the estimated variables (see Methods).</p>
</caption>
<graphic xlink:href="121517_fig6.tif"/>
</fig>
</sec>
<sec id="s3c">
<label>3.3</label>
<title>Effects of manganese</title>
<p>While processes A and B produced comparable glycoform distributions after day 10, the glycan fractions prior to this day, especially those of FA2 and the galactosylated structures, showed a completely different dynamic behavior. In order to elucidate the dynamic alterations in the IgG glycosylation caused by the change in the culture media composition and the addition of Mn, we computed the relative deviation in the viable cell density and in the (global) cell specific productivities (see <xref ref-type="fig" rid="fig7">Figure 7</xref>). The relative deviation between the two processes is computed as follows:
<disp-formula id="eqn11"><alternatives><graphic xlink:href="121517_eqn11.gif"/></alternatives></disp-formula> where <italic>z<sub>A</sub></italic> and <italic>z<sub>B</sub></italic> denote the variable of interest (i.e. the viable cell density and specific productivities) of process A and B, respectively. <xref ref-type="fig" rid="fig8">Figure 8</xref> further shows the relative deviation of the normalized glycosylation throughput for each enzyme <italic>J</italic>, defined as
<disp-formula id="eqn12"><alternatives><graphic xlink:href="121517_eqn12.gif"/></alternatives></disp-formula></p>
<p>Note that the summation in the numerator above is done over all fluxes catalysed by the enzyme <italic>J</italic>. The normalized flux throughput of an enzyme reflects the activity of the glycosylation reactions carried out by a particular enzyme relative to the total activity of all glycosylation reactions in the network.</p>
<fig id="fig7" position="float" fig-type="figure">
<label>Figure 7</label>
<caption>
<p>Relative deviations in (A) the viable cell density and (B) the cell specific productivity between process A and B. A positive (negative) value indicates that the variable is larger (smaller) in process B than in process A.</p>
</caption>
<graphic xlink:href="121517_fig7.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig7">Figure 7</xref> shows that the alternative culture media in process B led to a higher viable cell density but resulted in a lower specific productivity than process A. These observations suggested a trade-off between the cell growth and the antibody production upon changing the media composition. Except for fluxes catalysed by GalT, the normalized glycosylation throughputs in process B were roughly the same as those in process A for the entire cultivation period (see <xref ref-type="fig" rid="fig8">Figure 8</xref>). The normalized throughput of GalT showed a markedly more dynamic difference between the two processes. In particular, we observed a higher GalT normalized throughput in process B than in process A during the first half of the cell cultivation. This increase diminished with time and the relative deviation eventually dropped to roughly zero as with the other enzymes. Again, we did not compare the glycosylation fluxes catalysed by SiaT as the flux values were nearly zero (&#x223C;10<sup>&#x2212;3</sup> pg/cell/day).</p>
<fig id="fig8" position="float" fig-type="figure">
<label>Figure 8</label>
<caption>
<p>Relative deviations of the normalized flux throughput for each enzyme between process A and B. A positive (negative) value indicates that the variable is larger (smaller) in process B than in process A. The error bars correspond to the standard deviation in the estimated variables (see Methods).</p>
</caption>
<graphic xlink:href="121517_fig8.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<label>4.</label>
<title>Discussion</title>
<p>The combination of experimental and computational approaches, particularly using CBM, has brought a tremendous progress in metabolic engineering, for elucidating the regulation of cellular metabolism, for predicting the outcome of perturbations to the metabolic network (e.g. knock-outs), and for strain optimization (<xref ref-type="bibr" rid="c6">Bordbar et al., 2014</xref>). However, the CBM is not yet routinely applied to study the glycosylation network. Driven by the importance of understanding and controlling glycosylation of proteins, we created the glycosylation flux analysis by adapting the CBM approach for the glycosylation network. Based on a pseudo steady state assumption of the fluxes in the glycosylation network, the GFA generates dynamic glycosylation flux predictions using time-resolved measurements of cell culture data, particularly viable cell density, protein titer and glycan fractions. More specifically, the GFA captures the dynamic changes in the glycosylation fluxes using two pre-multiplicative factors; <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) that accounts for the (local) changes that occur in an enzyme-specific manner, and <italic>&#x03B2;</italic>(<italic>t</italic>) that accounts for the (global) alterations in cell metabolism that affects the cell specific productivity. Besides reducing the degrees of freedom in the flux prediction problem (due to the small number of enzymes in the glycosylation network), the use of pre-multiplicative factors above leads to the delineation of local and global effects of the process conditions on the protein glycosylation. In contrast to the more detailed differential equation based analyses of the glycosylation networks (<xref ref-type="bibr" rid="c18">Jedrzejewski et al., 2014</xref>; <xref ref-type="bibr" rid="c19">Jimenez del Val et al., 2011</xref>; <xref ref-type="bibr" rid="c20">Krambeck and Betenbaugh, 2005</xref>), the GFA, like the MFA, represents a parameter-free approach and requires only the stoichiometric matrix information. However, since the GFA involves solving the inverse problem &#x2013; estimating intracellular fluxes given dynamic cell culture data, this method cannot directly be used for predicting the effects of changing process parameters or genetic alterations on <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), <italic>&#x03B2;</italic>(<italic>t</italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline8.gif"/></alternatives></inline-formula> <italic>a priori</italic>.</p>
<p>There exist several implications from the formulation of intracellular glycosylation flux <italic>V<sub>I,j</sub></italic> that depends on three variables: <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), <italic>&#x03B2;</italic>(<italic>t</italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline9.gif"/></alternatives></inline-formula>. Starting with <italic>&#x03B2;</italic>(<italic>t</italic>), for fixed values of <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), a fold-increase (-decrease) in <italic>&#x03B2;</italic>(<italic>t</italic>) means an equal fold-increase (-decrease) among all of the glycosylation and secretion fluxes in the network (see SI Text B). Therefore, <italic>&#x03B2;</italic>(<italic>t</italic>) captures the global change in the glycosylation network, but such a change will not affect the glycan distribution in the monoclonal antibody. Meanwhile, for fixed values of <italic>&#x03B2;</italic>(<italic>t</italic>) and <inline-formula><alternatives><inline-graphic xlink:href="121517_inline10.gif"/></alternatives></inline-formula>, a variation in the enzyme-specific factors <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) will lead to a reorganization of the glycosylation fluxes and thus changes in the glycan distribution. The reorganization of the internal fluxes is restricted by constraints enforced by the flux balance equation in <xref ref-type="disp-formula" rid="eqn7">Eq. (7)</xref> (see SI Text B).Because all intracellular glycosylation fluxes associated with a particular enzyme <italic>J</italic> scale equally by <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>), the ratios among these fluxes thus remain constant with variations in <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>). Such ratios are given by the relative magnitudes of the corresponding <inline-formula><alternatives><inline-graphic xlink:href="121517_inline11.gif"/></alternatives></inline-formula>(see <xref ref-type="fig" rid="fig6">Figure 6</xref>). Finally, since <italic>&#x03B1;</italic><sub><italic>J</italic></sub>(<italic>t</italic>) and <italic>&#x03B2;</italic>(<italic>t</italic>) are set to 1 at the reference time point <italic>t</italic><sub><italic>ref</italic></sub>, <inline-formula><alternatives><inline-graphic xlink:href="121517_inline12.gif"/></alternatives></inline-formula> are the predictions for the intracellular glycosylation fluxes at this time point, i.e. <inline-formula><alternatives><inline-graphic xlink:href="121517_inline13.gif"/></alternatives></inline-formula>.</p>
<p>We applied the GFA to elucidate the glycosylation fluxes in two fed-batch cultivations of CHO cells producing IgG using different cell culture media. Our analyses showed that the temporal variation in the glycan distribution mainly resulted from the decrease in the galactosylation activity with time, relative to the other glycosylation reactions. We attributed this drop to the sensitivity of GalT activity to environmental changes, particularly the accumulation of ammonia in the cell culture. While the time profiles of the viable cell density and the specific productivity of IgG were similar between the two fed-batch processes, the changes in the glyoprofiles during the first half of the cultivations followed markedly different dynamics. The GFA showed that between day 3 and 6, the addition of Mn, a co-factor of GalT (<xref ref-type="bibr" rid="c26">Ramakrishnan et al., 2004</xref>). in process B increased the normalized galactosylation throughput. However, this increase largely disappeared by day 10. While Mn has also been reported to be a co-factor for GnTI/II (<xref ref-type="bibr" rid="c23">Nishikawast et al., 1988</xref>), under these cultivation conditions, the normalized glucosamination throughput in process B was roughly equal in that in process A. This observation suggested that the enzyme activity of GnTI/II might not be the rate-limiting factor of the IgG glucosamination in the two fed-batch cultivations.</p>
</sec>
<sec id="s5">
<label>5.</label>
<title>Conclusion</title>
<p>In this work, we adapted a constraint-based modeling approach to the analysis of protein glycosylation and developed the glycosylation flux analysis method. The GFA uses extracellular data of glycoform secretion fluxes and a (pseudo) steady state model of the glycosylation network to determine the intracellular glycosylation fluxes. In this regard, the GFA separates the influence of local enzyme-specific factors and global cell metabolism on each glycosylation flux. The ability to decouple the influences of local and global factors is important in elucidating the regulation of protein glycosylation and especially in efforts to control the outcome of the glycosylation process. The application of the GFA to two fed-batch cultivations of CHO cells for IgG production demonstrated the dynamic information that one could obtain from this analysis, specifically on the key glycosylation enzyme(s) that governed the resulting glycoform distribution. As more research efforts are invested in understanding protein glycosylation, producing a treasure trove of cell culture and glycoprofiling data, a network-based analysis method, like the GFA, will play an enabling role in generating insights into the complex intracellular regulation and control of the protein glycosylation process.</p>
</sec></body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors would like to thank Daniel Karst, Ernesto Scibona and Prof. Massimo Morbidelli as well as Robert Gauss and Prof. Markus Aebi for fruitful discussions. MS was partially supported by the Specific University Research grant number 20/2015. SH was supported by funding from ETH Zurich.</p>
</ack>
<sec sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>David Br&#x00FC;hlmann, Matthieu Stettler and Herv&#x00E9; Broly are employees of Merck Biopharma.</p>
</sec>
<glossary>
<title>Symbols</title>
<def-list>
<def-item><term><italic>&#x03B1;</italic></term><def><p>Enzyme specific factor</p></def></def-item>
<def-item><term><italic>&#x03B2;</italic></term><def><p>Specific productivity</p></def></def-item>
<def-item><term><italic>c</italic></term><def><p>Concentration</p></def></def-item>
<def-item><term><italic>c<sub>E</sub></italic></term><def><p>Extracellular concentration</p></def></def-item>
<def-item><term><italic>f</italic></term><def><p>Fraction</p></def></def-item>
<def-item><term><italic>K</italic></term><def><p>Number of time points</p></def></def-item>
<def-item><term><italic>m</italic></term><def><p>Number of glycoforms</p></def></def-item>
<def-item><term><italic>MW</italic></term><def><p>Molecular weight</p></def></def-item>
<def-item><term><italic>n</italic></term><def><p>Number of reactions</p></def></def-item>
<def-item><term><italic>S</italic></term><def><p>Stoichiometric matrix</p></def></def-item>
<def-item><term><italic>T</italic></term><def><p>Titer</p></def></def-item>
<def-item><term>t</term><def><p>Time</p></def></def-item>
<def-item><term><italic>V</italic></term><def><p>Volume</p></def></def-item>
<def-item><term><italic>V<sub>E</sub></italic></term><def><p>Secretion flux</p></def></def-item>
<def-item><term><italic>V<sub>I</sub></italic></term><def><p>Intracellular flux</p></def></def-item>
<def-item><term><italic>V<sup>ref</sup>I</italic></term><def><p>Reference fluxX</p></def></def-item>
<def-item><term><italic>X<sub>v</sub></italic></term><def><p>Viable cell density</p></def></def-item>
</def-list></glossary>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>CBM</term><def><p>Constraint-based modelling</p></def></def-item>
<def-item><term>CHO</term><def><p>Chinese hamster ovarian</p></def></def-item>
<def-item><term>ER</term><def><p>Endoplasmic reticulum</p></def></def-item>
<def-item><term>FBA</term><def><p>Flux balance analysis</p></def></def-item>
<def-item><term>GFA</term><def><p>Glycosylation flux analysis</p></def></def-item>
<def-item><term>IgG</term><def><p>Immunoglobulin G</p></def></def-item>
<def-item><term>MFA</term><def><p>Metabolic flux analysis</p></def></def-item>
<def-item><term>PAT</term><def><p>Process analytical technology</p></def></def-item>
<def-item><term>QbD</term><def><p>Quality by design</p></def></def-item>
<def-item><term>UPLC</term><def><p>Ultra performance liquid chromatography</p></def></def-item>
</def-list></glossary>
<glossary>
<title>Glycosylation nomenclature</title>
<def-list>
<def-item><term>Man</term><def><p>Mannosidase</p></def></def-item>
<def-item><term>GnT</term><def><p>N-Acetylglucosaminyltransferase</p></def></def-item>
<def-item><term>FucT</term><def><p>Fucosyltransferase</p></def></def-item>
<def-item><term>GalT</term><def><p>Galactosyltransferase</p></def></def-item>
<def-item><term>SiaT</term><def><p>Sialyltransferase</p></def></def-item>
<def-item><term>M9</term><def><p>Man<sub>9</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>M8</term><def><p>Man<sub>8</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>M7</term><def><p>Man<sub>7</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>M6</term><def><p>Man<sub>6</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>M5</term><def><p>Man<sub>5</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>A1</term><def><p>GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>A2</term><def><p>GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub></p></def></def-item>
<def-item><term>FA1</term><def><p>GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2</term><def><p>GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA1G1</term><def><p>GalGlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2G1-1</term><def><p>&#x03B1;(1-6)GalGlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2G2S1-2</term><def><p>&#x03B1;(1 -3)GalGlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2G2</term><def><p>Gal<sub>2</sub>GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2G2S1-1</term><def><p>&#x03B1;(1 -6)SiaGal<sub>2</sub>GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
<def-item><term>FA2G2S1-2</term><def><p>&#x03B1;(1-3)SiaGal<sub>2</sub>GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>Fuc</p></def></def-item>
</def-list></glossary>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Aebi</surname>, <given-names>M.</given-names></string-name>, <year>2013</year>. <article-title>N-linked protein glycosylation in the ER</article-title>. <source>Biochim. Biophys. Acta - Mol. Cell Res</source>. <volume>1833</volume>, <fpage>2430</fpage>&#x2013;<lpage>2437</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.04.001</pub-id></mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Aebi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hennet</surname>, <given-names>T.</given-names></string-name>, <year>2001</year>. <article-title>Congenital disorders of glycosylation: genetic model systems lead the way</article-title>. <source>Trends Cell Biol</source>. <volume>11</volume>, <fpage>136</fpage>&#x2013;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0962-8924(01)01925-0</pub-id></mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Aghamohseni</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ohadi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Spearman</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Krahn</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Moo-Young</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Scharer</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Butler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Budman</surname>, <given-names>H.M.</given-names></string-name>, <year>2014</year>. <article-title>Effects of nutrient levels and average culture pH on the glycosylation pattern of camelid-humanized monoclonal antibody</article-title>. <source>J. Biotechnol</source>. <volume>186</volume>, <fpage>98</fpage>&#x2013;<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jbiotec.2014.05.024</pub-id></mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Arosio</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Rima</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Morbidelli</surname>, <given-names>M.</given-names></string-name>, <year>2013</year>. <article-title>Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates</article-title>. <source>Pharm. Res</source>. <volume>30</volume>, <fpage>641</fpage>&#x2013;<lpage>654</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11095-012-0885-3</pub-id></mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Bibila</surname>, <given-names>T.A.</given-names></string-name>, <string-name><surname>Flickinger</surname>, <given-names>M.C.</given-names></string-name>, <year>1991</year>. <article-title>A model of interorganelle monoclonal antibody transport and secretion in mouse hybridoma cells</article-title>. <source>Biotechnol. Bioeng</source>. <volume>38</volume>, <fpage>767</fpage>&#x2013;<lpage>780</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bit.260380711</pub-id></mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Bordbar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Monk</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>King</surname>, <given-names>Z.A.</given-names></string-name>, <string-name><surname>Palsson</surname>, <given-names>B.O.</given-names></string-name>, <year>2014</year>. <article-title>Constraint-based models predict metabolic and associated cellular functions</article-title>. <source>Nat. Rev. Genet</source>. <volume>15</volume>, <fpage>107</fpage>&#x2013;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrg3643</pub-id></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Egea</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Henriques</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Cokelaer</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Villaverde</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>MacNamara</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Danciu</surname>, <given-names>D.-P.</given-names></string-name>, <string-name><surname>Banga</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Saez-Rodriguez</surname>, <given-names>J.</given-names></string-name>, <year>2014</year>. <article-title>MEIGO: an open-source software suite based on metaheuristics for global optimization in systems biology and bioinformatics</article-title>. <source>BMC Bioinformatics</source> <volume>15</volume>, <fpage>136</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2105-15-136</pub-id></mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="other"><collab>FDA</collab>, <year>2004</year>. <article-title>Guidance for Industry</article-title>. <source>PAT &#x2014; A Framework for Innovative Pharmaceutical DEvelopment, Mannufacturing, and Quality Assurance</source> <fpage>19</fpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Gawlitzek</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ryll</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Lofgren</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sliwkowski</surname>, <given-names>M.B.</given-names></string-name>, <year>2000</year>. <article-title>Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms</article-title>. <source>Biotechnol. Bioeng</source>. <volume>68</volume>, <fpage>637</fpage>&#x2013;<lpage>646</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(SICI)1097-0290(20000620)68:6&#x003C;637::AID-BIT6&#x003E;3.0.CO;2-C</pub-id></mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Goh</surname>, <given-names>J.S.Y.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>K.F.</given-names></string-name>, <string-name><surname>Wan</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Teo</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>Z.</given-names></string-name>, <year>2014</year>. <article-title>Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT I function</article-title>. <source>Biotechnol. J</source>. <volume>9</volume>, <fpage>100</fpage>&#x2013;<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1002/biot.201300301</pub-id></mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="other"><string-name><surname>Goudar</surname>, <given-names>C.T.</given-names></string-name>, <string-name><surname>Biener</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Piret</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Konstantinov</surname>, <given-names>K.B.</given-names></string-name>, <year>2007</year>. <article-title>Metabolic flux estimation in mammalian cell cultures, in: Methods in Biotechnology</article-title>. <source>Springer</source>, pp. <fpage>301</fpage>&#x2013;<lpage>317</lpage>. doi:<pub-id pub-id-type="doi">10.1002/btpr.284</pub-id></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Goudar</surname>, <given-names>C.T.</given-names></string-name>, <string-name><surname>Joeris</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Konstantinov</surname>, <given-names>K.B.</given-names></string-name>, <string-name><surname>Piret</surname>, <given-names>J.M.</given-names></string-name>, <year>2005</year>. <article-title>Logistic equations effectively model Mammalian cell batch and fed-batch kinetics by logically constraining the fit</article-title>. <source>Biotechnol. Prog</source>. <volume>21</volume>, <fpage>1109</fpage>&#x2013;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bp050018j</pub-id></mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Harding</surname>, <given-names>F.A.</given-names></string-name>, <string-name><surname>Stickler</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Razo</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>DuBridge</surname>, <given-names>R.B.</given-names></string-name>, <year>2010</year>. <article-title>The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions</article-title>. <source>MAbs</source> <volume>2</volume>, <fpage>256</fpage>&#x2013;<lpage>265</lpage>. doi:<pub-id pub-id-type="doi">10.4161/mabs.2.3.11641</pub-id></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Hendrickson</surname>, <given-names>T.L.</given-names></string-name>, <string-name><surname>Imperiali</surname>, <given-names>B.</given-names></string-name>, <year>1995</year>. <article-title>Metal ion dependence of oligosaccharyl transferase: implications for catalysis</article-title>. <source>Biochemistry</source> <volume>34</volume>, <fpage>9444</fpage>&#x2013;<lpage>9450</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi00029a020</pub-id></mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="supplementary-material"><string-name><surname>Hirschberg</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lippincott-Schwartz</surname>, <given-names>J.</given-names></string-name>, <year>1999</year>. <article-title>Secretory pathway kinetics and in vivo analysis of protein traffic from the Golgi complex to the cell surface</article-title>. <source>Faseb J</source> <volume>13</volume> Suppl 2, <fpage>S251</fpage>&#x2013;<lpage>S256</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Hossler</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Khattak</surname>, <given-names>S.F.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Z.J.</given-names></string-name>, <year>2009</year>. <article-title>Optimal and consistent protein glycosylation in mammalian cell culture</article-title>. <source>Glycobiology</source> <volume>19</volume>, <fpage>936</fpage>&#x2013;<lpage>949</lpage>. doi:<pub-id pub-id-type="doi">10.1093/glycob/cwp079</pub-id></mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Ivarsson</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Villiger</surname>, <given-names>T.K.</given-names></string-name>, <string-name><surname>Morbidelli</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Soos</surname>, <given-names>M.</given-names></string-name>, <year>2014</year>. <article-title>Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation</article-title>. <source>J. Biotechnol</source>. <volume>188C</volume>, <fpage>88</fpage>&#x2013;<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jbiotec.2014.08.026</pub-id></mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Jedrzejewski</surname>, <given-names>P.M.</given-names></string-name>, <string-name><surname>del Val</surname>, <given-names>I.J.</given-names></string-name>, <string-name><surname>Constantinou</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Dell</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Haslam</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Polizzi</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Kontoravdi</surname>, <given-names>C.</given-names></string-name>, <year>2014</year>. <article-title>Towards controlling the glycoform: A model framework linking extracellular metabolites to antibody glycosylation</article-title>. <source>Int. J. Mol. Sci</source>. <volume>15</volume>, <fpage>4492</fpage>&#x2013;<lpage>4522</lpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms15034492</pub-id></mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Jimenez del Val</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Nagy</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Kontoravdi</surname>, <given-names>C.</given-names></string-name>, <year>2011</year>. <article-title>A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus</article-title>. <source>Biotechnol. Prog</source>. <volume>27</volume>, <fpage>1730</fpage>&#x2013;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1002/btpr.688</pub-id></mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Krambeck</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Betenbaugh</surname>, <given-names>M.J.</given-names></string-name>, <year>2005</year>. <article-title>A mathematical model of N-linked glycosylation</article-title>. <source>Biotechnol. Bioeng</source>. <volume>92</volume>, <fpage>711</fpage>&#x2013;<lpage>728</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bit.20645</pub-id></mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Vijayasankaran</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Shen</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kiss</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Amanullah</surname>, <given-names>A.</given-names></string-name>, <year>2010</year>. <article-title>Cell culture processes for monoclonal antibody production</article-title>. <source>MAbs</source> <volume>2</volume>, <fpage>466</fpage>&#x2013;<lpage>479</lpage>. doi:<pub-id pub-id-type="doi">10.4161/mabs.2.5.12720</pub-id></mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Puri</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Neelamegham</surname>, <given-names>S.</given-names></string-name>, <year>2013</year>. <article-title>Glycosylation Network Analysis Toolbox: a MATLAB-based environment for systems glycobiology</article-title>. <source>Bioinformatics</source> <volume>29</volume>, <fpage>404</fpage>&#x2013;<lpage>406</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/bts703</pub-id></mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Nishikawast</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Peggs</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Paulsenll</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Schachters</surname>, <given-names>H.</given-names></string-name>, <year>1988</year>. <article-title>Control of glycoprotein synthesis. Purification and characterization of rabbit liver UDP-N-acetylglucosamine: alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I</article-title>. <source>J. Biol. Chem</source>. <volume>263</volume>, <fpage>8270</fpage>&#x2013;<lpage>8281</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Orth</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Thiele</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Palsson</surname>, <given-names>B.&#x00D8;.</given-names></string-name>, <year>2010</year>. <article-title>What is flux balance analysis?</article-title> <source>Nat. Biotechnol</source>. <volume>28</volume>, <fpage>245</fpage>&#x2013;<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt.1614.What</pub-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Pacis</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Autsen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bayer</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>F.</given-names></string-name>, <year>2011</year>. <article-title>Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform</article-title>. <source>Biotechnol. Bioeng</source>. <volume>108</volume>, <fpage>2348</fpage>&#x2013;<lpage>2358</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bit.23200</pub-id></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Ramakrishnan</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Boeggeman</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ramasamy</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Qasba</surname>, <given-names>P.K.</given-names></string-name>, <year>2004</year>. <article-title>Structure and catalytic cycle of beta-1,4-galactosyltransferase</article-title>. <source>Curr. Opin. Struct. Biol</source>. <volume>14</volume>, <fpage>593</fpage>&#x2013;<lpage>600</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sbi.2004.09.006</pub-id></mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Rathore</surname>, <given-names>A.S.</given-names></string-name>, <year>2009</year>. <article-title>Roadmap for implementation of quality by design (QbD) for biotechnology products</article-title>. <source>Trends Biotechnol</source>. <volume>27</volume>, <fpage>546</fpage>&#x2013;<lpage>553</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2009.06.006</pub-id></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Sha</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Agarabi</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Brorson</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>D.-Y.</given-names></string-name>, <string-name><surname>Yoon</surname>, <given-names>S.</given-names></string-name>, <year>2016</year>. <article-title>N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies</article-title>. <source>Trends Biotechnol</source>. <volume>34</volume>, <fpage>835</fpage>&#x2013;<lpage>846</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2016.02.013</pub-id></mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Shah</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Kuntz</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Rose</surname>, <given-names>D.R.</given-names></string-name>, <year>2008</year>. <article-title>Golgi alpha-mannosidase II cleaves two sugars sequentially in the same catalytic site</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <volume>105</volume>, <fpage>9570</fpage>&#x2013;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0802206105</pub-id></mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="other"><string-name><surname>Spahn</surname>, <given-names>P.N.</given-names></string-name>, <string-name><surname>Hansen</surname>, <given-names>A.H.</given-names></string-name>, <string-name><surname>Henning</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Arnsdorf</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kildegaard</surname>, <given-names>H.F.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>N.E.</given-names></string-name>, <string-name><surname>Arnsdorf</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kildegaard</surname>, <given-names>H.F.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>N.E.</given-names></string-name>, <string-name><surname>Markov</surname>, <given-names>A.</given-names></string-name>, <year>2015</year>. <article-title>A Markov chain model for N-linked protein glycosylation &#x2013; towards a low-parameter tool for model-driven</article-title>. <source>Metab. Eng</source>. <fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2015.10.007</pub-id></mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Spahn</surname>, <given-names>P.N.</given-names></string-name>, <string-name><surname>Hansen</surname>, <given-names>A.H.</given-names></string-name>, <string-name><surname>Kol</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Voldborg</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>N.E.</given-names></string-name>, <year>2017</year>. <article-title>Predictive glycoengineering of biosimilars using a Markov chain glycosylation model</article-title>. <source>Biotechnol. J</source>. <volume>12</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>.doi:<pub-id pub-id-type="doi">10.1002/biot.201600489</pub-id></mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>St Amand</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Tran</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Radhakrishnan</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Robinson</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>Ogunnaike</surname>, <given-names>B. a</given-names></string-name>, <year>2014</year>. <article-title>Controllability analysis of protein glycosylation in CHO cells</article-title>. <source>PLoS One</source> <volume>9</volume>, <fpage>e87973</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0087973</pub-id></mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Tharmalingam</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>C.-H.</given-names></string-name>, <string-name><surname>Callahan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>T Goudar</surname>, <given-names>C.</given-names></string-name>, <year>2015</year>. <article-title>A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture</article-title>. <source>Biotechnol. Bioeng</source>. <volume>112</volume>, <fpage>1146</fpage>&#x2013;<lpage>1154</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bit.25520</pub-id></mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Uma&#x00F1;a</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Bailey</surname>, <given-names>J.E.</given-names></string-name>, <year>1997</year>. <article-title>A Mathematical Model of N-Linked Glycoform Biosynthesis</article-title>. <source>Biotechnol. Bioeng</source>. <volume>55</volume>, <fpage>890</fpage>&#x2013;<lpage>908</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(SICI)1097-0290(19970920)55:6&#x003C;890::AID-BIT7&#x003E;3.0.CO;2-B</pub-id></mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Uma&#x00F1;a</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Jean-Mairet</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Moudry</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Amstutz</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Bailey</surname>, <given-names>J.E.</given-names></string-name>, <year>1999</year>. <article-title>Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity</article-title>. <source>Nat. Biotechnol</source>. <volume>17</volume>, <fpage>176</fpage>&#x2013;<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1038/6179</pub-id></mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="other"><string-name><surname>Villiger</surname>, <given-names>T.K.</given-names></string-name>, <string-name><surname>Scibona</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Stettler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Broly</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Morbidelli</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Soos</surname>, <given-names>M.</given-names></string-name>, <year>2016</year>. <article-title>Controlling the time evolution of mAb N-linked glycosylation - Part II: Model-based predictions</article-title>.<source>Biotechnol. Prog</source>. doi:<pub-id pub-id-type="doi">10.1002/btpr.2315</pub-id></mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="other"><string-name><surname>Zhang</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Kaufman</surname>, <given-names>R.J.</given-names></string-name>, <year>2006</year>. <article-title>Protein folding in the endoplasmic reticulum and the unfolded protein response</article-title>., in: <source>Handbook of Experimental Pharmacology</source>. pp. <fpage>69</fpage>&#x2013;<lpage>91</lpage>.</mixed-citation></ref></ref-list>
</back>
</article>